{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:00:10Z","timestamp":1785276010181,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2018R1D1A1A02086109"],"award-info":[{"award-number":["NRF-2018R1D1A1A02086109"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bisphosphonate-induced osteonecrosis of the jaw (BRONJ) presents with a typical pattern of jaw necrosis in patients who have been prescribed bisphosphonates (BPs) and other antiangiogenetic drugs to treat osteoporosis or bone-related complications of cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study divided 38 patients with BRONJ into two groups according to the prescribing causes: cancer (<jats:italic>n\u2009<\/jats:italic>=\u200913) and osteoporosis (<jats:italic>n\u2009<\/jats:italic>=\u200925), and underwent whole exome sequencing and compared them with normal controls (<jats:italic>n\u2009<\/jats:italic>=\u200990). To identify candidate genes and variants, we conducted three analyses: a traditional genetic model, gene-wise variant score burden, and rare-variant analysis methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The stop-gain mutation (rs117889746) of the <jats:italic>PZP<\/jats:italic> gene in the BRONJ cancer group was significantly identified in the additive trend model analysis. In the cancer group, <jats:italic>ARIDS<\/jats:italic>, <jats:italic>HEBP1<\/jats:italic>, <jats:italic>LTBP1<\/jats:italic>, and <jats:italic>PLVAP<\/jats:italic> were identified as candidate genes. In the osteoporosis group, <jats:italic>VEGFA<\/jats:italic>, <jats:italic>DFFA<\/jats:italic>, and <jats:italic>FAM193A<\/jats:italic> genes showed a significant association. No significant genes were identified in the rare-variant analysis pipeline. Biologically accountable functions related to BRONJ occurrence-angiogenesis-related signaling (<jats:italic>VEGFA<\/jats:italic> and <jats:italic>PLVAP<\/jats:italic> genes), TGF-\u03b2 signaling (<jats:italic>LTBP1<\/jats:italic> and <jats:italic>PZP<\/jats:italic> genes), heme toxicity (<jats:italic>HEBP1<\/jats:italic>) and osteoblast maturation (<jats:italic>ARIDS<\/jats:italic>)-were shown in candidate genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study showed that the candidate causative genes contributing to the development of BRONJ differ according to the BP dose and background disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-019-2129-3","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T14:02:57Z","timestamp":1574258577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-7020","authenticated-orcid":false,"given":"Kye Hwa","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hyen","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joo","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Juyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younggyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMct1004903","volume":"363","author":"MJ Favus","year":"2010","unstructured":"Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363:2027\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"2129_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.coms.2015.06.005","volume":"27","author":"PL Fung","year":"2015","unstructured":"Fung PL, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Oral Maxillofac Surg Clin N Am. 2015;27(4):537\u201346.","journal-title":"Oral Maxillofac Surg Clin N Am"},{"issue":"2","key":"2129_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2015","unstructured":"Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002\u20132012. Bone. 2015;57(2):423\u20138.","journal-title":"Bone"},{"issue":"10","key":"2129_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"S-B Woo","year":"2006","unstructured":"Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2129_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479\u201391.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2129_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00784-013-1012-5","volume":"18","author":"P Rugani","year":"2014","unstructured":"Rugani P, et al. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Investig. 2014;18(2):401\u20137.","journal-title":"Clin Oral Investig"},{"issue":"2","key":"2129_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","volume":"8","author":"IR Reid","year":"2012","unstructured":"Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2012;8(2):90\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2129_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, et al. American Association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"2129_CR9","doi-asserted-by":"publisher","first-page":"e0118084","DOI":"10.1371\/journal.pone.0118084","volume":"10","author":"JH Kim","year":"2015","unstructured":"Kim JH, et al. Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics. PLoS ONE. 2015;10(2):e0118084.","journal-title":"PLoS ONE"},{"issue":"7","key":"2129_CR10","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","volume":"112","author":"ME Sarasquete","year":"2008","unstructured":"Sarasquete ME, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112(7):2709\u201312.","journal-title":"Blood"},{"issue":"7","key":"2129_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/odi.12355","volume":"21","author":"H Choi","year":"2015","unstructured":"Choi H, Lee J, Lee J-H, Kim J-H. Genetic association between VEGF polymorphisms and BRONJ in the Korean population. Oral Dis. 2015;21(7):866\u201371.","journal-title":"Oral Dis"},{"issue":"6","key":"2129_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0714.2010.01004.x","volume":"40","author":"PG Arduino","year":"2011","unstructured":"Arduino PG, et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med. 2011;40(6):510\u20135.","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"2129_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1601-0825.2012.01912.x","volume":"18","author":"B Balla","year":"2012","unstructured":"Balla B, et al. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw. Oral Dis. 2012;18(6):580\u20135.","journal-title":"Oral Dis"},{"issue":"6","key":"2129_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","volume":"40","author":"J Katz","year":"2011","unstructured":"Katz J, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2011;40(6):605\u201311.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2129_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.2011.08622.x","volume":"154","author":"MT Di Martino","year":"2011","unstructured":"Di Martino MT, et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol. 2011;154:529\u201333. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08622.x.","journal-title":"Br J Haematol"},{"key":"2129_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bone.2019.04.010","volume":"124","author":"G Yang","year":"2019","unstructured":"Yang G, et al. Pharmacogenomics of osteonecrosis of the jaw. Bone. 2019;124:75\u201382. https:\/\/doi.org\/10.1016\/j.bone.2019.04.010.","journal-title":"Bone"},{"key":"2129_CR17","first-page":"364","volume":"3","author":"F Marini","year":"2011","unstructured":"Marini F, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed). 2011;3:364\u201370.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"1","key":"2129_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jbmr.3285","volume":"33","author":"G Yang","year":"2018","unstructured":"Yang G, et al. SIRT1\/HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis. J Bone Miner Res. 2018;33(1):91\u20138.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2129_CR19","doi-asserted-by":"publisher","first-page":"e0213860","DOI":"10.1371\/journal.pone.0213860","volume":"14","author":"KH Lee","year":"2019","unstructured":"Lee KH, Min BJ, Kim JH. Personal genome testing on physicians improves attitudes on pharmacogenomic approaches. PLoS ONE. 2019;14(3):e0213860.","journal-title":"PLoS ONE"},{"key":"2129_CR20","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3899\/jrheum.100221","volume":"38","author":"AA Khan","year":"2011","unstructured":"Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 2011;38:1396\u2013402.","journal-title":"J Rheumatol"},{"key":"2129_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.joms.2009.01.003","volume":"67","author":"LA Assael","year":"2009","unstructured":"Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg. 2009;67:35\u201343.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"2129_CR22","first-page":"35","volume":"15","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet. 2012;15(3):35.","journal-title":"Front Genet"},{"issue":"13","key":"2129_CR23","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"Pauline C Ng","year":"2003","unstructured":"Ng Pauline C, Henikoff Steven. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2129_CR24","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2018","unstructured":"Rentzsch P, et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2018;47(D1):D886\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"2129_CR25","doi-asserted-by":"publisher","first-page":"e0162135","DOI":"10.1371\/journal.pone.0162135","volume":"11","author":"KH Lee","year":"2016","unstructured":"Lee KH, et al. Genome sequence variability predicts drug precautions and withdrawals from the market. PLoS ONE. 2016;11(9):e0162135.","journal-title":"PLoS ONE"},{"issue":"1","key":"2129_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12920-018-0323-4","volume":"11","author":"H Seo","year":"2018","unstructured":"Seo H, et al. Deleterious genetic variants in ciliopathy genes increase risk of ritodrine-induced cardiac and pulmonary side effects. BMC Med Genomics. 2018;11(1):4.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"2129_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ajhg.2011.05.029","volume":"89","author":"MC Wu","year":"2011","unstructured":"Wu MC, et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82\u201393.","journal-title":"Am J Hum Genet"},{"key":"2129_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Genomes Project Consortium, Auton A, Brooks LD. A global reference for human genetic variation. Nature. 2015;526:68\u201374.","journal-title":"Nature"},{"key":"2129_CR29","first-page":"285","volume":"30","author":"M Lek","year":"2015","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2015;30:285\u201391.","journal-title":"Nature"},{"key":"2129_CR30","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. https:\/\/www.R-project.org\/."},{"issue":"9","key":"2129_CR31","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1186\/gb-2007-8-9-r183","volume":"8","author":"DW Huang","year":"2007","unstructured":"Huang DW, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183.","journal-title":"Genome Biol"},{"issue":"4","key":"2129_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/path.1805","volume":"206","author":"LA Strickland","year":"2005","unstructured":"Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD, Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J Pathol. 2005;206(4):466\u201375.","journal-title":"J Pathol"},{"issue":"2","key":"2129_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","volume":"17","author":"P Nicoletti","year":"2012","unstructured":"Nicoletti P, et al. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist. 2012;17(2):279\u201387.","journal-title":"Oncologist"},{"key":"2129_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcms.2012.10.018","volume":"41","author":"P Stockmann","year":"2013","unstructured":"Stockmann P, et al. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2013;41:71\u20135.","journal-title":"J Craniomaxillofac Surg"},{"key":"2129_CR35","first-page":"579","volume":"6","author":"BC English","year":"2010","unstructured":"English BC, et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag. 2010;6:579\u201383.","journal-title":"Ther Clin Risk Manag"},{"key":"2129_CR36","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1080\/10428194.2017.1300889","volume":"58","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, et al. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017;58:2304\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2129_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/bmm.12.14","volume":"6","author":"F La Ferla","year":"2012","unstructured":"La Ferla F, et al. An aromatase polymorphism (g.132810C\u2009>\u2009T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. Biomark Med. 2012;6:201\u20139.","journal-title":"Biomark Med"},{"issue":"10","key":"2129_CR38","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3324\/haematol.2011.042572","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, et al. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica. 2011;96(10):1557\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"2129_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1348-8643(12)00045-6","volume":"10","author":"Ikebe Tetsuro","year":"2013","unstructured":"Tetsuro Ikebe. Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw. Oral Sci Int. 2013;10(1):1\u20138.","journal-title":"Oral Sci Int"},{"issue":"8","key":"2129_CR40","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1007\/PL00004164","volume":"9","author":"Russell","year":"1999","unstructured":"Russell, et al. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(8):S66\u201380.","journal-title":"Osteoporos Int"},{"issue":"13","key":"2129_CR41","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt BA, et al. The carboxyl-terminal domain (111165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271(13):7788\u201395.","journal-title":"J Biol Chem"},{"issue":"D1","key":"2129_CR42","doi-asserted-by":"publisher","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","volume":"45","author":"A Bateman","year":"2017","unstructured":"Uniprot consortium T, Bateman A, Martin MJ, O\u2019Donovan C, Magrane M, Alpi E, Antunes R, et al. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017;45(D1):D158\u201369.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2129_CR43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1432-1033.1994.tb18781.x","volume":"221","author":"A Philip","year":"1994","unstructured":"Philip A, Bostedt L, Stigbrand T, O\u2019Connor\u2010Mccourt MD. Binding of transforming growth factor-\u03b2 (TGF-\u03b2) to pregnancy zone protein (PZP). Eur J Biochem. 1994;221(2):687\u201393.","journal-title":"Eur J Biochem"},{"issue":"2","key":"2129_CR44","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1172\/JCI113647","volume":"82","author":"J Pfeilschifter","year":"1998","unstructured":"Pfeilschifter J, Seyedin SM, Mundy GR. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J Clin Invest. 1998;82(2):680\u20135.","journal-title":"J Clin Invest"},{"key":"2129_CR45","unstructured":"\u00c5str\u00f6m P. Regulatory mechanisms mediating matrix metalloproteinase-8 effects in oral tissue repair and tongue cancer. University of Oulu. 2014."},{"key":"2129_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fphar.2017.00146","volume":"8","author":"S Immenschuh","year":"2017","unstructured":"Immenschuh S, Vijayan V, Janciauskiene S, Gueler F. Heme as a target for therapeutic interventions. Front Pharmacol. 2017;8:146.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2129-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:14:25Z","timestamp":1605744865000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2129-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2129-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"24 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research involving human subjects and their genomic data was approved by the institutional review boards of Asan Medical Center and Seoul St. Mary\u2019s Hospital (IRB nos. 2014-1216 and KC15TIMI0055, respectively). The control subjects were recruited and approved by the institutional review boards of Seoul National University Hospital (IRB no. 1507-093-689). Written informed consent was obtained from each subject prior to their participation. We confirmed the checklist according to the STROBE guidelines and satisfied all items.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"381"}}